The present invention refers to aminaphtone, i.e. 2-hydroxy-3-methyl-1,4-naphthohydroquinone-2-p-aminobenzoate, for use in the treatment and/or prevention of migraine, preferably generated by inflammatory vascular problems in human beings. Said aminaphtone can be administered at an amount comprised between 50 and 150 mg per dose, preferably about 75 mg per dose, from two to four times per day.
